Drugs / FT522
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05950334 | Nov 2023 → Jun 2025 | B-cell non-Hodgkin lymphoma | Fate Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT522 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05950334 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT05950334 ↗ |